Clinical Trials on Drug Combination in Japan

Total 18 results

SymBio Pharmaceuticals

Completed

Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects

Drug Drug Interaction

Japan
Nihon Pharmaceutical Co., Ltd

Completed

Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.

Stevens-Johnson Syndrome | Toxic Epidermal Necrolysis

Japan
Andreas Benesic, MD
MetaHeps GmbH

Unknown

Cells of Monocytic Origin as Surrogate Markers for Individual Drug Effects and Hepatotoxicity

Adverse Reaction to Drug | Drug-induced Disorder of Liver

Hong Kong, Australia, Germany, Japan, Korea, Republic of
Eisai Co., Ltd.

Active, not recruiting

A Study of Equfina® on the Incidences of Adverse Drug Reactions in Participants With Parkinson's Disease (Including Participants With Hepatic Impairment)

Parkinson Disease

Japan
Associations for Establishment of Evidence in Interventions
Medtronic Vascular

Completed

A Prospective Multicenter Post Approval Study to Evaluate the Long-term Safety and Efficacy of the Resolute Integrity in the Japanese All-comers Patients With Coronary Artery Disease (PROPEL)

Coronary Artery Disease | Drug-eluting Stent

Japan
Hokkaido University Hospital
Merck Sharp & Dohme LLC

Recruiting

Docetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma

Effect of Drug

Japan
Osaka City University

Completed

Prevention of CHOP-induced Chronic Cardiotoxicity

Non-Hodgkin's Lymphoma

Japan
SymBio Pharmaceuticals

Completed

Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma

Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL

Japan
Duke University
Christian Doppler University Hospital

Enrolling by invitation

5-SENSE Score Validation Study

Epilepsy Intractable

United States, Spain, Australia, Austria, Canada, Czechia, Denmark, France, Germany, Japan, Romania, Switzerland
UCB Biopharma SRL

Terminated

A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy (DUET)

Drug-Resistant Epilepsy | Focal-Onset Seizures

United States, Australia, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerlan... and more
UCB Biopharma SRL

Terminated

Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

Drug-Resistant Epilepsy | Focal-Onset Seizures

United States, Australia, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Lithuania, Mexico, Poland, Romania, Serbia, Slovakia, Spain, Turk... and more
UCB Biopharma S.P.R.L.

Completed

Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy (ARISE)

Focal-Onset Seizures | Drug-resistant Epilepsy

United States, Australia, Belgium, Bulgaria, Canada, Czechia, France, Germany, Hungary, Italy, Japan, Lithuania, Mexico, Poland, Portugal, Slovakia, Spain, Turkey, United Kingdom
University Hospital, Lille

Completed

Pre-stroke Cognitive Status and Thrombolytic Therapy (OPHELIE-COG)

Brain Ischemia | Dementia | Adverse Effect of Thrombolytic Drugs | Impaired Cognition

France, Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia

Tardive Dyskinesia

Japan
LivaNova

Active, not recruiting

Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System. (CORE-VNS)

Epilepsy | Seizures | Drug Resistant Epilepsy

Australia, Italy, United States, Israel, United Kingdom, Canada, Brazil, Japan, Belgium, India, Austria, China, Netherlands, Poland, Portugal, Saudi Arabia
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)

Tuberculosis, Pulmonary | Extensively Drug-Resistant Tuberculosis | Tuberculosis, Multidrug Resistant

Korea, Republic of, China, United States, Egypt, Estonia, Japan, Latvia, Peru, Philippines
PTC Therapeutics

Completed

A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy (MIT-E)

Mitochondrial Diseases | Drug Resistant Epilepsy | Leigh Disease | Leigh Syndrome | Mitochondrial Encephalopathy (MELAS) | Pontocerebellar Hypoplasia Type 6 (PCH6) | Alpers Disease | Alpers Syndrome

United States, Spain, United Kingdom, Canada, France, Italy, Poland, Sweden, Japan
Eli Lilly and Company

Active, not recruiting

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3)

Urogenital Neoplasms | Prostatic Neoplasms | Neoplasm Metastasis | Enzyme Inhibitors | Antineoplastic Agents | Hormones | Physiological Effects of Drugs | Antineoplastic Agents, Hormonal | Androgens | Hormones, Hormone Substitutes, and Hormone Antagonists | Abiraterone Acetate | Steroid Synthesis Inhibitors | Cytochrome... and other conditions

China, Canada, France, United States, Australia, Czechia, Hungary, Spain, Germany, Japan, Taiwan, Netherlands, Turkey, Mexico, Belgium, Korea, Republic of, Argentina, Romania, United Kingdom, Italy, Israel, Brazil, Poland, Greece

Clinical Trials on Drug Combination in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations